The major concern about a powerful new gene-editing technique that most people don't want to talk about
By Tanya Lewis,
Business Insider
| 12. 02. 2015
Scientists, bioethicists, and members of the public have descended on Washington, DC this week for an international meeting to discuss the ethics of a promising lab technique that lets scientists edit our genes.
The technique, known as CRISPR/Cas9, lets scientists cut-and-paste DNA inside cells to correct genetic defects or, potentially, add new capabilities. It offers enormous promise to improve our understanding of biology and to treat or even eliminate genetic diseases.
But there's a dark side to manipulating our genetics that few want to discuss: Eugenics, the racist practice of trying to "improve" the human race by controlling genetics and reproduction.
A disturbingly widespread practice
While eugenics is most commonly associated with Nazi Germany, it was alive and well in the US and in other countries well before World War II, Daniel Kevles, a historian of science at New York University, said during a talk at the gene editing summit on Tuesday.
"Eugenics was not unique to the Nazis. It could — and did — happen everywhere," Kevles said.
He and others worry that gene editing tools like CRISPR...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...